Delivery Order SPE2DB22D9239-SPE2DB25FDH36
Award Date
3/19/25
Potential Completion Date
4/9/25
Potential Value
$15K
Federal Agency
Defense Logistics Agency
Awardee
DMS Pharmaceutical Group Inc.
Ultimate Awardee
Not listed
NAICS Category
424210 - Drugs and Druggists' Sundries Merchant Wholesalers
PSC Category
6505 - Drugs And Biologicals
Federal Contract Vehicle
Set-Aside Type
No Set-Aside Used
Extent Competed
Full and Open Competition
Major Defense Program
Not listed
Pricing Type
Firm Fixed Price
Place of Performance
Park Ridge, IL 60068, USA
Solicitation Procedures
Negotiated Proposal / Quote
Number Of Offers Received
Not listed
Legislative Mandate
Not listed
National Interest Action
Not listed
Research Type
Not listed
Primary Consortia Member
Not listed
Similar Awards
This federal contract award to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler, was issued by the Defense Logistics Agency (DLA) under the Medical Supply Chain division. The $13,539.75 firm fixed-price delivery order is for the supply of XOLAIR 150 MG/ML SYRINGEML, with a period of performance through September 17, 2024. DMS Pharmaceutical Group holds a significant $499,999,999 indefinite delivery contract (IDC) with the DLA under the SPE2DB program, which...
This federal contract award to DMS Pharmaceutical Group Inc., a woman-owned small business, is a delivery order valued at $15,474.00 issued by the Defense Logistics Agency (DLA). The contract is for the provision of XOLAIR 150 MG/ML SYRINGEML, a specialized pharmaceutical product. The award does not have a set-aside designation. The contract is part of a larger Indefinite Delivery Contract (IDC) valued at $499,999,999 that DMS Pharmaceutical Group holds with the DLA under the SPE2DB program....
This federal contract award was issued by the Defense Logistics Agency (DLA) to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois. The $15,474.00 firm fixed-price delivery order is for the supply of XOLAIR 150 MG/ML SYRINGEML, a specialized pharmaceutical product, with a period of performance through January 2, 2025. DMS Pharmaceutical Group Inc. holds a $499,999,999 Indefinite Delivery Contract (IDC) with the DLA under the SPE2DB...
This federal contract award to DMS Pharmaceutical Group Inc., a woman-owned small business, was issued by the Defense Logistics Agency (DLA), a component of the U.S. Department of Defense (DoD). The $4,642.20 firm fixed-price delivery order is for the supply of XOLAIR 150 MG/ML SYRINGEML, a specialty pharmaceutical product, to fulfill the recurring medical supply needs of military health facilities. The award is not associated with any set-aside program. DMS Pharmaceutical Group holds a...
This federal contract award to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler, is for the delivery of Xolair 150 mg/ml syringes. The $9,284.40 firm fixed-price delivery order was issued by the Defense Logistics Agency's (DLA) Medical Supply Chain division, which supports the recurring pharmaceutical needs of Department of Defense (DoD) and Department of Veterans Affairs (VA) healthcare facilities nationwide. DMS Pharmaceutical Group holds a significant...
This federal contract award to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler, is a delivery order valued at $7,737.00 for the supply of XOLAIR 150 MG/ML SYRINGEML to the Defense Logistics Agency (DLA), which is the primary logistics and supply agency for the U.S. Department of Defense. The contract has an ultimate completion date of March 4, 2025 and is a firm fixed-price delivery order, with no set-aside designation. DMS Pharmaceutical Group Inc. holds...
This federal contract award to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler, is a $1,547.40 firm fixed-price delivery order issued by the Defense Logistics Agency (DLA) under the SPE2DB program. The contract is for the supply of XOLAIR 150 MG/ML SYRINGE, a specialized pharmaceutical product, with an ultimate completion date of August 12, 2024. DMS Pharmaceutical Group holds a significant $499,999,999 indefinite delivery contract (IDC) with the DLA under...
This federal contract award to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler, is a firm fixed-price Delivery Order (SPE2DB23FQ60G) valued at $15,474.00 for the supply of XOLAIR 150 MG/ML syringes. The contract is awarded under the Defense Logistics Agency's (DLA) SPE2DB program, a $499,999,999 indefinite delivery contract (IDC) that runs through December 31, 2025. This IDC allows the DLA to issue delivery orders to DMS Pharmaceutical Group for a...
This is a firm fixed-price delivery order awarded to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler, by the Defense Logistics Agency (DLA). The $11,605.50 award is for the supply of XOLAIR 150 MG/ML syringes, with a performance period through December 19, 2023. DMS Pharmaceutical Group holds a significant $499,999,999 indefinite delivery contract (IDC) with the DLA under the SPE2DB program, which allows the agency to issue firm fixed-price delivery orders...
This federal contract award to DMS Pharmaceutical Group Inc., a woman-owned small business, is a delivery order worth $3,868.50 for the provision of Xolair 150 mg/mL syringes. The contract is a firm fixed-price award with no set-aside designation, awarded by the Defense Logistics Agency (DLA) under the Medical Supply Chain program. DMS Pharmaceutical Group holds a significant $499,999,999 indefinite delivery contract (IDC) with the DLA, which allows the agency to issue delivery orders for a wide...